Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis of chronic myelomonocytic leukemia.
Catalano L, Improta S, de Laurentiis M, Molica S, Majolino I, Musto P, Fragasso A, De Placido S, Rotoli B. Catalano L, et al. Among authors: fragasso a. Haematologica. 1996 Jul-Aug;81(4):324-9. Haematologica. 1996. PMID: 8870376
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.
Gentile M, Cutrona G, Fabris S, Pesce EA, Baldini L, Di Raimondo F, Musolino C, Di Tonno P, Di Renzo N, Molica S, Brugiatelli M, Ilariucci F, Zupo S, Matis S, Maura F, Vigna E, Angrilli F, Recchia AG, Quarta G, Iannitto E, Fragasso A, Musto P, Spriano M, Vincelli I, Vallisa D, Cortelezzi A, Mauro FR, Foà R, Federico M, Neri A, Ferrarini M, Morabito F. Gentile M, et al. Among authors: fragasso a. Am J Hematol. 2013 Jul;88(7):539-44. doi: 10.1002/ajh.23448. Epub 2013 Jun 12. Am J Hematol. 2013. PMID: 23553682 Free article. Clinical Trial.
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Voso MT, Niscola P, Piciocchi A, Fianchi L, Maurillo L, Musto P, Pagano L, Mansueto G, Criscuolo M, Aloe-Spiriti MA, Buccisano F, Venditti A, Tendas A, Piccioni AL, Zini G, Latagliata R, Filardi N, Fragasso A, Fenu S, Breccia M; GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry. Voso MT, et al. Among authors: fragasso a. Eur J Haematol. 2016 Apr;96(4):344-51. doi: 10.1111/ejh.12595. Epub 2015 Jun 21. Eur J Haematol. 2016. PMID: 26018238
Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.
D'Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, Vigliotti ML, Nunziata G, Fragasso A, Villa MR, Grossi A, Selleri C, Deaglio S, La Sala A, Del Poeta G, Simeon V, Aliberti L, De Martino L, Giudice A, Musto P, De Feo V. D'Arena G, et al. Among authors: fragasso a. Leuk Lymphoma. 2014 Apr;55(4):841-7. doi: 10.3109/10428194.2013.803223. Epub 2013 Oct 17. Leuk Lymphoma. 2014. PMID: 23829282
Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.
Trino S, De Luca L, Simeon V, Laurenzana I, Morano A, Caivano A, La Rocca F, Pietrantuono G, Bianchino G, Grieco V, Signorino E, Fragasso A, Bochicchio MT, Venturi C, Rosti G, Martinelli G, Del Vecchio L, Cilloni D, Musto P. Trino S, et al. Among authors: fragasso a. Tumour Biol. 2016 Jan;37(1):217-25. doi: 10.1007/s13277-015-3772-9. Epub 2015 Jul 21. Tumour Biol. 2016. PMID: 26194865
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.
Fabris S, Mosca L, Cutrona G, Lionetti M, Agnelli L, Ciceri G, Barbieri M, Maura F, Matis S, Colombo M, Gentile M, Recchia AG, Anna Pesce E, Di Raimondo F, Musolino C, Gobbi M, Di Renzo N, Mauro FR, Brugiatelli M, Ilariucci F, Lipari MG, Angrilli F, Consoli U, Fragasso A, Molica S, Festini G, Vincelli I, Cortelezzi A, Federico M, Morabito F, Ferrarini M, Neri A. Fabris S, et al. Among authors: fragasso a. Am J Hematol. 2013 Jan;88(1):24-31. doi: 10.1002/ajh.23340. Epub 2012 Oct 9. Am J Hematol. 2013. PMID: 23044996 Free article. Clinical Trial.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A. Musto P, et al. Among authors: fragasso a. Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23. Ann Hematol. 2019. PMID: 30353388
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Sacchi S, Marcheselli R, Lazzaro A, Morabito F, Fragasso A, Di Renzo N, Balleari E, Neri S, Quarta G, Ferrara R, Vigliotti ML, Polimeno G, Musto P, Consoli U, Zoboli A, Buda G, Pastorini A, Masini L. Sacchi S, et al. Among authors: fragasso a. Leuk Lymphoma. 2011 Oct;52(10):1942-8. doi: 10.3109/10428194.2011.584006. Epub 2011 Jun 12. Leuk Lymphoma. 2011. PMID: 21663513 Clinical Trial.
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Bari A, Marcheselli R, Marcheselli L, Alvarez I, Pozzi S, Ferri P, Lazzaro A, Fragasso A, Neri S, Baldini L, Carella AM, Angrilli F, Guariglia R, Buda G, Stelitano C, Sacchi S; Gruppo Italiano Studio Linfomi (GISL). Bari A, et al. Among authors: fragasso a. Acta Haematol. 2017;137(1):7-14. doi: 10.1159/000449052. Epub 2016 Nov 4. Acta Haematol. 2017. PMID: 27820922 Free article. Clinical Trial.
69 results